DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 trea...
Source: finanznachrichten.de